Panbela Therapeutics
Panbela Therapeutics, Inc. (NASDAQ: PBLA) is a clinical-stage pharmaceutical company developing small molecule drugs targeting the polyamine metabolism pathway for the treatment of pancreatic cancer and other gastrointestinal malignancies characterized by dysregulated polyamine biosynthesis. According to its website at panbelatherapeutics.com, the company's lead drug candidate SBH-101 (formerly known as ivospemin) is an investigational combination regimen that pairs a polyamine biosynthesis inhibitor with a polyamine transport blocker to achieve comprehensive depletion of intracellular polyamines in cancer cells — exploiting the elevated polyamine requirements of rapidly proliferating cancer cells to selectively impair tumor growth. Panbela's science is grounded in decades of research demonstrating that polyamines — naturally occurring molecules essential for cell growth and proliferation — are present at dramatically elevated levels in pancreatic and other gastrointestinal cancers.
Panbela Therapeutics' clinical development program, described at panbelatherapeutics.com, focuses on advancing SBH-101 through clinical trials in pancreatic cancer — one of the most lethal malignancies, with a five-year survival rate below 15% for all stages combined — where the extremely poor outcomes with existing treatments create compelling clinical need for new therapeutic approaches. The company has conducted Phase 1/2 clinical investigations evaluating SBH-101 in pancreatic cancer patients in combination with standard chemotherapy regimens, generating preliminary evidence of the combination's tolerability and anti-tumor activity. Panbela's development strategy seeks to build on these early clinical results through more advanced clinical trials designed to establish the safety and efficacy profile required to support regulatory approval.
Panbela Therapeutics is listed on Nasdaq and pursues its clinical development activities with the support of the National Cancer Institute and other research collaborators who have provided both scientific expertise and funding for aspects of the polyamine metabolism research underlying the company's drug development programs. According to panbelatherapeutics.com, the NCI collaboration reflects the strength of the scientific rationale for targeting polyamine metabolism in pancreatic cancer and provides Panbela with access to institutional research resources and clinical network connections that support the advancement of its clinical programs. Panbela Therapeutics' combination of polyamine pathway targeting mechanism, pancreatic cancer clinical focus, NCI collaboration support, and Nasdaq-listed structure reflects its positioning as a clinical-stage oncology company pursuing scientifically grounded new approaches to treating one of the most difficult cancers.